Copyright
©The Author(s) 2019.
World J Clin Oncol. Sep 24, 2019; 10(9): 307-317
Published online Sep 24, 2019. doi: 10.5306/wjco.v10.i9.307
Published online Sep 24, 2019. doi: 10.5306/wjco.v10.i9.307
Table 1 DNA isolation protocols
PureLink Genomic DNA mini kit (Invitrogen–ma-nual) | Time | iPrep genomic DNA kit (Invitrogen–aut-omated) | Time | High Pure FFPE DNA isolation kit (Rochemanual) | Time | MagnaPure LC DNA Isolation kit (Roche–automated) | Time |
3 sections of 5 µm | 5-10 min | 3 sections of 5 µm | 5-10 min | 3 sections of 5 µm | 5-10 min | 3 sections of 5 µm | 5-10 min |
Deparaffinizatio-n using Xylol 3 times | 3 x 10 min | Deparaffinization using Xylol 3 times | 3 x 10 min | Deparaffinization using Xylol 3 times | 3 x 10 min | Deparaffinization using Xylol 3 times | 3 x 10 min |
Lysis and digestion (20 µL of ProtK) | From 30 min to overnight | Sample lysis | Lysis and digestion (70 µL ProtK) | 30-90 min | Sample lysis and binding | ||
Binding DNA to silica membranes (columns) | 15 min | Binding DNA to magnetic beads | 30 min | Binding DNA to silica membranes (columns) | 15 min | ProtK | 30 min |
Washing out contaminants | 15 min | Magnetic separation of beads | Washing out contaminants | 15 min | Binding DNA to beads | ||
Eluting | 3 min | Separation of liquid solutions from beads Washing beads eluting | Eluting | 3 min | Washing out contaminants Washing beads eluting | ||
~ 1.96 Euro/sample | ~ 7.8 Euro/sample | ~ 3.66 Euro/sample | ~ 6.81 Euro/sample |
Table 2 DNA concentration (ng/µL) using four commercially kits for DNA isolation
PureLink Genomic DNA mini kit (Invitrogen–manual) | iPrep genomic DNA kit (Invitrogen–automated) | MagnaPure LC DNA Isolation kit (Roche–automated) | High Pure FFPE DNA isolation kit (Roche–manual) | |
Mean | 157.24 | 8.72 | 20.39 | 86.64 |
Standard deviation | 62.99 | 6.40 | 21.19 | 43.84 |
Minimum | 37.60 | 0.70 | 0.30 | 4.20 |
Maximum | 316 | 29.80 | 121 | 168.90 |
Table 3 DNA quality1 using four commercially kits for DNA isolation
PureLink Genomic DNA mini kit (Invitrogen–manual) | iPrep genomic DNA kit (Invitrogen–automated) | MagnaPure LC DNA Isolation kit (Roche–automated) | High Pure FFPE DNA isolation kit (Roche–manual) | |
Mean | 1.80 | 1.78 | 1.84 | 2.19 |
Standard deviation | 0.04 | 0.14 | 0.52 | 0.37 |
Minimum | 1.67 | 1.42 | 0.99 | 1.60 |
Maximum | 3.10 | 2.25 | 4.36 | 3.10 |
Table 4 Correlation between DNA concentration1 and clinicopathological aspects of colorectal cancer
Characteristics | Number | DNA concentration PureLink Genomic DNA mini kit (manual) | P value | ||
≤ 150 ng/µL | > 150 ng/µL | ||||
Age | ≤ 60 | 20 | 12 | 8 | 0.373 |
> 60 | 26 | 11 | 15 | ||
Gender | Male | 26 | 15 | 11 | 0.373 |
Female | 20 | 8 | 12 | ||
Macroscopic aspect | Polypoid | 10 | 4 | 15 | 0.00103 |
Ulcero-infiltrative | 36 | 19 | 8 | ||
Microscopic aspect | G1 | 13 | 3 | 10 | 0.043 |
G2 + G3 | 33 | 20 | 13 | ||
Localization | Proximal colon | 8 | 5 | 3 | 0.892 |
Distal colon | 21 | 11 | 10 | ||
Rectum | 17 | 7 | 10 | ||
Depth of infiltration (pT stage) | T2-T3 T4 | 40 6 | 20 3 | 20 3 | > 0.992 |
Lymph node metastasis (pN stage) | Present (pN1-3) | 17 | 13 | 4 | 0.063 |
Absent (pN0) | 29 | 10 | 19 | ||
Lymph node ratio | < 0.15 | 36 | 17 | 19 | 0.723 |
≥ 0.15 | 10 | 6 | 4 |
Table 5 Correlation between DNA concentration1 and clinicopathological aspects of colorectal cancer
Characteristics | Number | iPrep genomic DNA kit (magnetic beads) | P value | ||
≤ 10 ng/µL | > 10 ng/µL | ||||
Age | ≤ 60 | 20 | 12 | 8 | 0.093 |
> 60 | 26 | 22 | 4 | ||
Gender | Male | 26 | 19 | 7 | 0.993 |
Female | 20 | 15 | 5 | ||
Macroscopic aspect | Polypoid | 10 | 3 | 7 | 0.00043 |
Ulcero-infiltrative | 36 | 31 | 5 | ||
Microscopic aspect | G1 | 13 | 4 | 9 | < 0.00013 |
G2 + G3 | 33 | 30 | 3 | ||
Localization | Proximal colon | 8 | 6 | 2 | 0.522 |
Distal colon | 21 | 17 | 4 | ||
Rectum | 17 | 11 | 6 | ||
Depth of infiltration (pT stage) | T2-T3 T4 | 40 6 | 28 6 | 12 0 | 0.112 |
Lymph node metastasis (pN stage) | Present (pN1-3) | 17 | 14 | 3 | 0.313 |
Absent (pN0) | 29 | 20 | 9 | ||
Lymph node ratio | < 0.15 | 36 | 25 | 11 | 0.253 |
≥ 0.15 | 10 | 9 | 1 |
Table 6 Correlation between DNA concentration1 and clinicopathological aspects of colorectal cancer
Characteristics | Number | High Pure FFPE DNA isolation kit (manual) | P value | ||
< 100 ng/µL | ≥ 100 ng/µL | ||||
Age | ≤ 60 | 20 | 12 | 8 | 0.993 |
> 60 | 26 | 15 | 11 | ||
Gender | Male | 26 | 15 | 11 | 0.993 |
Female | 20 | 12 | 8 | ||
Macroscopic aspect | Polypoid | 10 | 8 | 17 | 0.123 |
Ulcero-infiltrative | 36 | 19 | 2 | ||
Microscopic aspect | G1 | 13 | 3 | 10 | 0.0023 |
G2 + G3 | 33 | 24 | 9 | ||
Localization | Proximal colon | 8 | 5 | 3 | 0.962 |
Distal colon | 21 | 12 | 9 | ||
Rectum | 17 | 10 | 7 | ||
Depth of infiltration (pT stage) | T2-T3 T4 | 40 6 | 24 3 | 16 3 | 0.642 |
Lymph node metastasis (pN stage) | Present (pN1-3) | 17 | 8 | 9 | 0.353 |
Absent (pN0) | 29 | 19 | 10 | ||
Lymph node ratio | < 0.15 | 36 | 23 | 13 | 0.273 |
≥ 0.15 | 10 | 4 | 6 |
Table 7 Correlation between DNA concentration1 and clinicopathological aspects of colorectal cancer
Characteristics | P value | MagnaPure LC DNA Isolation kit (magnetic beads) | P value | ||
< 20 ng/µL | ≥ 20 ng/µL | ||||
Age | ≤ 60 | 20 | 12 | 8 | 0.383 |
> 60 | 26 | 12 | 14 | ||
Gender | Male | 26 | 12 | 14 | 0.383 |
Female | 20 | 12 | 8 | ||
Macroscopic aspect | Polypoid | 10 | 8 | 2 | 0.043 |
Ulcero-infiltrative | 36 | 16 | 20 | ||
Microscopic aspect | G1 | 13 | 4 | 9 | 0.023 |
G2 + G3 | 33 | 23 | 10 | ||
Localization | Proximal colon | 8 | 3 | 5 | 0.602 |
Distal colon | 21 | 11 | 10 | ||
Rectum | 17 | 10 | 7 | ||
Depth of infiltration (pT stage) | T2-T3 | 40 | 20 | 20 | 0.442 |
T4 | 6 | 4 | 2 | ||
Lymph node metastasis (pN stage) | Present (pN1-3) | 17 | 5 | 12 | 0.033 |
Absent (pN0) | 29 | 19 | 10 | ||
Lymph node ratio | < 0.15 | 36 | 18 | 18 | 0.723 |
≥ 0.15 | 10 | 6 | 4 |
- Citation: Kovacs Z, Jung I, Csernak E, Szentirmay Z, Banias L, Rigmanyi G, Gurzu S. DNA extraction from paraffin embedded colorectal carcinoma samples: A comparison study of manual vs automated methods, using four commercially kits. World J Clin Oncol 2019; 10(9): 307-317
- URL: https://www.wjgnet.com/2218-4333/full/v10/i9/307.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i9.307